Replies to post #163735 on Biotech Values

[DewDiligence]

ACHN—Any further mention of sovaprevir adversely reacting with ritonavir in the DDI study?

The consensus view is that Reyataz—not ritonavir—was responsible for the huge increase in ACH-1625 plasma concentration.

[DewDiligence]

ENTA/ABBV—…tolerability in the real world setting can only be reduced by multiple classes of DAA's including ritonavir.

The proof is in the pudding. To date, the tolerability of the regimen in question has been quite good, as evidenced by the results from the phase-2 AVIATOR study.